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ARTICLE
Optimal dosing of dihydroartemisinin-piperaquine
for seasonal malaria chemoprevention in young
children
Palang Chotsiri1, Issaka Zongo2, Paul Milligan 3, Yves Daniel Compaore 2, Anyirékun Fabrice Somé2,
Daniel Chandramohan4, Warunee Hanpithakpong1, François Nosten 5,6, Brian Greenwood4,
Philip J. Rosenthal7, Nicholas J. White1,5, Jean-Bosco Ouédraogo2 & Joel Tarning 1,5
Young children are the population most severely affected by Plasmodium falciparum malaria.
Seasonal malaria chemoprevention (SMC) with amodiaquine and sulfadoxine-pyrimethamine
provides substantial beneﬁt to this vulnerable population, but resistance to the drugs will
develop. Here, we evaluate the use of dihydroartemisinin-piperaquine as an alternative
regimen in 179 children (aged 2.33–58.1 months). Allometrically scaled body weight on
pharmacokinetic parameters of piperaquine result in lower drug exposures in small children
after a standard mg per kg dosage. A covariate-free sigmoidal EMAX-model describes the
interval to malaria re-infections satisfactorily. Population-based simulations suggest that
small children would beneﬁt from a higher dosage according to the WHO 2015 guideline.
Increasing the dihydroartemisinin-piperaquine dosage and extending the dose schedule to
four monthly doses result in a predicted relative reduction in malaria incidence of up to 58%
during the high transmission season. The higher and extended dosing schedule to cover the
high transmission period for SMC could improve the preventive efﬁcacy substantially.
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Malaria is one of the most important infectious diseases inhumans. In areas of intense malaria transmission chil-dren, who have yet to develop protective immunity, are
especially vulnerable to malaria. In 2017, ~61% of worldwide
malaria-related mortality occurred in children below the age of 5
years1. Intermittent preventive treatment of malaria consists of a
full antimalarial treatment regimen given at regular intervals in
order to eliminate any existing infections and to produce sufﬁ-
ciently high residual drug concentrations to prevent new infec-
tions until the next dose is given or the need diminishes.
Intermittent preventive treatment of malaria has been shown to
be beneﬁcial for high-risk populations, such as pregnant women
in sub-Saharan Africa2–4. In addition, seasonal malaria chemo-
prevention (SMC), i.e. intermittent preventive treatment during
the high-transmission season, is recommended for children living
in regions of high yet seasonal malaria transmission, principally
the Sahelian regions of West Africa. Intermittent preventive
therapy in pregnancy relies on sulfadoxine-pyrimethamine (SP)
and SMC on SP plus amodiaquine. In the sub-Sahel areas where
SMC is being used, SP plus amodiaquine currently remains
effective but resistance is likely to develop5. In parts of SE Africa,
where malaria is highly seasonal and SMC could potentially be
used, SMC is not recommended because of resistance to SP.
Dihydroartemisinin-piperaquine (DHA-PQ) is a potential alter-
native regimen for SMC in young children in areas where there is
resistance to SP3,4,6.
The ﬁxed-dose antimalarial drug combination of oral DHA-PQ
is an attractive alternative for SMC. It can be administered once
daily for three days. A large pooled analysis of 12 different studies
in 6 countries between 2006 and 2009 showed excellent efﬁcacy
(98.7% at day 28) and safety (4.8% total incidence of early
vomiting) in the treatment of uncomplicated Plasmodium falci-
parum malaria7. The pharmacokinetic properties of DHA-PQ
have been described in various patient groups and in healthy
volunteers8–10. Dihydroartemisinin is a rapidly eliminated but
potent artemisinin derivative that kills a large proportion of the
infecting malaria parasite biomass. Three days of treatment
exposes two asexual cycles in P. falciparum infections to the drug.
In contrast, piperaquine is eliminated slowly with a long terminal
elimination half-life (20–30 days). Piperaquine is responsible for
killing the residual parasites in the body, which remain after three
days of dihydroartemisinin and thereby prevents recrudescent
malaria. The long terminal elimination half-life of piperaquine
also provides a long post-treatment prophylactic effect, which
lasts at least four weeks if adequate doses are given and fully
sensitive parasites are prevalent. Piperaquine is eliminated pri-
marily by metabolism by cytochrome P450 3A4 (CYP3A4)11,12.
Piperaquine is a highly lipophilic molecule and studies have
shown that the absorption can increase with up to 121% (95% CI:
26-216%) if administered together with a high fat meal13,14.
However, administration with a low fat meal demonstrated no
increased absorption15,16.
The pharmacokinetic and pharmacodynamic characteristics of
DHA-PQ support its use in SMC. A study from Uganda reported
prophylactic efﬁcacies of monthly DHA-PQ chemoprevention in
children of 31% (95% CI: 6–49%), 67% (95% CI: 54–76%), and
97% (95% CI: 89–99%) in the low, median, and high piperaquine
exposure groups, respectively17. A full 3-day treatment regimen
of DHA-PQ given monthly for 9 months was well tolerated and
resulted in a high protection rate of 98% (95% CI: 96–99%)
against P. falciparum malaria in adults at high risk of malaria on
the Thailand-Myanmar border18,19. Chemoprevention in young
children receiving monthly DHA-PQ resulted in a three year
protective efﬁcacy of 58% (95% CI: 7–44%), and was superior to
both monthly SP and daily trimethoprim-sulfamethoxazole20.
This protective efﬁcacy was lower than expected because of poor
drug adherence. On the other hand, a chemoprevention study in
schoolchildren receiving monthly supervised DHA-PQ showed a
remarkably high protective effect, i.e. reduced malaria incidence
by 96% (95% CI: 88–99%) and reduced asymptomatic malaria by
94% (95% CI: 19–56%)21. Preventive efﬁcacy of DHA-PQ
has been shown in Southeast Asia in the treatment of P. vivax
malaria, where the drug combination eliminated blood stage
parasites rapidly and suppressed a large proportion of the ﬁrst
relapses, which emerge usually three weeks after the acute
infection22. When used in the treatment of young children with
acute uncomplicated P. falciparum malaria, the original manu-
facturer recommended treatment regimen provides sub-optimal
plasma concentrations of piperaquine10,23. Limited information is
available on the pharmacokinetic and pharmacodynamic prop-
erties of DHA-PQ when used for malaria prevention in young
children.
The primary aim of this study was to investigate the phar-
macokinetic and pharmacodynamic properties of piperaquine in
SMC for young children in Burkina Faso and thereby inform
optimum dosing. The ﬁnal pharmacokinetic–pharmacodynamic
model was used to simulate protective effects against malaria with
different treatment regimens.
Results
Study demographic and data. This study included a total of 741
children who received oral DHA-PQ in a clinical trial [6] of SMC
(Table 1). The nested pharmacokinetic–pharmacodynamic
(PKPD) group included 179 children and the pharmacodynamic
(PD) group included 562 children. Only the children in the PKPD
group provided blood samples for drug measurements. The
pharmacokinetic and pharmacodynamic model was developed
based on patients in the PKPD group, and the data from the
children in the PD group were used as an external validation of
the ﬁnal pharmacodynamic time-to-event model. Of the 741
apparently healthy children enroled in the study, 42.1% (312) had
a positive blood smear for P. falciparum malaria at the beginning
of the study, and 21.9% (162) and 36.9% (274) of children
acquired at least one new malaria episode during the three rounds
of monthly SMC and the 2 months of follow-up, respectively. The
median time to new infections was 90 days post-enrolment
(range: 13–153 days). Twenty-two children (3.0%) were lost to
follow-up. Children who received SMC with SP and amodiaquine
in the original trial had a slightly lower incidence of malaria
(19.5%) during the three months of active treatment6.
A total of 26, 82, and 40 children provided capillary plasma
samples (466 capillary samples) and 6, 10, and 15 children
provided venous plasma samples (71 venous samples) during the
ﬁrst, second, and third study months, respectively. Only 1 of 466
capillary plasma samples and 3 out of 71 venous plasma samples
were measured to be below the lower limit of quantiﬁcation
(LLOQ) for piperaquine, and were omitted from the subsequent
pharmacokinetic–pharmacodynamic analysis. Non-linear mixed-
effects modelling was performed in order to characterise the
pharmacokinetic and pharmacodynamic properties of
piperaquine.
Pharmacokinetic model. The pharmacokinetic model was
developed based on the data from capillary and venous plasma
concentrations of the children in the PKPD group (n= 179). Due
to the sparsity of measured drug concentrations, a frequentist
prior approach was used in order to stabilize the estimation of
typical pharmacokinetic parameters and inter-individual varia-
bility. Observed capillary plasma piperaquine concentration-time
data were described accurately by a two-transit-compartment
absorption model, followed by a three compartment distribution
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model as reported previously10. Venous and capillary piperaquine
plasma concentrations were modelled simultaneously by esti-
mating a venous-capillary conversion factor at a population level
(illustrated in the Supplementary Figure 1). The present study
showed a signiﬁcantly lower exposure to piperaquine compared
to the prior model. This was, therefore, corrected for by imple-
menting a categorical covariate on the relative bioavailability.
Including an enzyme maturation effect on oral clearance during
the ﬁrst two years of age improved the model ﬁt signiﬁcantly, but
resulted in an unrealistic and poorly estimated enzyme matura-
tion half-life (TM50) of less than one month. Therefore, the
maturation effect was omitted in the ﬁnal pharmacokinetic
model. No other covariates were signiﬁcant in the stepwise
addition and elimination covariate approach. Final pharmacoki-
netic parameter estimates and relative standard errors are pre-
sented in the Table 2 and secondary pharmacokinetic parameter
estimates are presented in Supplementary Table 1.
The ﬁnal model described the observed concentration-time
proﬁles accurately with no major model misspeciﬁcation
(Supplementary Figure 2), and with good predictive performance
(Fig. 1a). A numerical predictive check resulted in 3.8% (95% CI:
3.00–7.52%) and 6.4% (95% CI: 2.82–7.33%) of the observed data
being above and below the simulated 90% prediction interval,
respectively. Eta and epsilon shrinkages were relatively high in the
ﬁnal model because of the sparseness of the observed data: CL/
F= 54%, VC/F= 46%, Q2/F= 74%, VP2/F= 65%, MTT= 76%,
F= 21%, and σ= 26.8%. Bootstrapping the ﬁnal pharmacokinetic
model showed robust parameter estimates with acceptable
relative standard errors.
Pharmacodynamic model. Overall, 58.5% of children (436/741)
presented with malaria during the 4 months study period
(3 rounds of monthly SMC and 2 months of passive follow-up).
Median time to recurrent malaria was 90 days (range:
13–153 days) after starting the study, corresponding to approxi-
mately one month after the last study treatment. The children in
the PKPD group had a slightly higher malaria incidence com-
pared to those in the PD group (62.3% vs. 57.3%, respectively).
An interval-censoring time-to-event model was applied
successfully to the children in the PKPD group, using
parasitaemia-corrected back-extrapolation to the time of emer-
gence from the pre-erythocytic liver stage infections (illustrated in
the supplementary Figure 3). This model was suggested by
Bergstrand et al.19 and it provides a more mechanistic under-
standing of recurrent malaria infections. A constant baseline
hazard model with a sigmoidal EMAX antimalarial effect relation-
ship of piperaquine concentrations and study outcome was
superior to other models. The model also contained a ﬁxed
dihydroartemisinin effect, reducing the hazard of reinfection to
zero during each treatment occasion because of the very potent
parasite elimination effect of dihydroartemisinin. No covariate
effects on the pharmacodynamic parameters were found using a
stepwise covariate approach. Time-to-malaria infection in the PD
group was used as an external validation of the ﬁnal
pharmacokinetic–pharmacodynamic model. A visual predictive
check of the time-to-event model showed good predictive
performance, both for the internal (Fig. 1b and Supplementary
Figure 4) and external (Fig. 1c and Supplementary Figure 5)
validation. Bootstrapping showed robust parameter estimates
with acceptable relative standard errors.
The minimum inhibitory concentration (MIC) of piperaquine
was estimated in these children based on the predicted
piperaquine concentrations at the start of novel blood stage
infections, using the same back-extrapolation methodology
described above. The upper (95th) percentile of these drug
concentrations is assumed to be the highest possible concentra-
tion which still allows parasite replication. Thus, the predicted
MIC values in these patients (i.e. the 95th percentile of
piperaquine venous plasma concentrations at the start of blood
stage infection) were between 12.9 ng mL−1 and 17.5 ng mL−1
(equivalent to capillary blood concentrations of 33.9 ng mL−1 and
45.5 ng mL−1, respectively) based on the start and the end of the
likely time period of new parasites emerging from the liver
(illustrated in the Supplementary Figure 6).
Dosing regimen simulations. A high proportion (33.3%, 6/28
and 60.9%, 84/138) of observed day 7 piperaquine venous and
capillary plasma concentrations were below a threshold for
therapeutic success of 30 ng mL−1 and 57 ng mL−1, respectively,
previously deﬁned for the treatment falciparum malaria10,24.
Table 1 Clinical study demographics, sample collection, and treatment outcomes
Parameter PKPD group (primary analysis) PD group (external validation) Total
Total no. of children 179 562 741
Total no. of samples (capillary/venous plasma) 466/71 NA NA
Total monthly dose of piperaquine base (mg kg−1) 29.2 (18.0–39.0) 29.7 (16.7–55.4) 29.7 (16.7–55.4)
Total monthly dose of dihydroartemisinin (mg kg−1) 6.32 (3.90–8.45) 6.43 (3.61–12.0) 6.43 (3.61–12.0)
Continuous and categorical covariates at admission
Age (months) 32.1 (2.33–58.1) 24.0 (3.00–59.3) 26.1 (2.33–59.3)
Body weight (kg) 11.0 (4.20–18.3) 10.5 (5.00–21.0) 10.6 (4.20–21.0)
Axillary temperature at admission (ºC) 36.7 (35.0–39.3) 36.7 (35.0–40.4) 36.7 (35.0–40.4)
Number of patients with malaria (%) 71 (39.6%) 250 (44.5%) 312 (42.1%)
Number of male patients (%) 93 (51.9%) 277 (49.3%) 370 (49.9%)
Treatment outcomes during follow-up
Number of patients with malaria (%) 110 (61.4%) 322 (57.3%) 432 (58.2%)
Time-to malaria (days) 107 (28–149) 90 (13–153) 90 (13–153)
Parasitaemia in patients with malaria (parasites μL−1) 48,926 (64–1,496,212) 36,081 (12–260,000) 39,275 (12–1,496,212)
Number of patients lost before day 90 (%) 4 (2.19%) 18 (3.20%) 22 (2.95%)
Follow-up time of lost patients (days) 60 (60–62) 60.5 (20–80) 60 (20–89)
Data from the children in the PKPD group were used to develop the pharmacokinetic and pharmacodynamic model, and the data from the children in the PD group (no blood samples collected) were
used for external validation of the ﬁnal pharmacodynamic model. All values are given as median (range) unless otherwise indicated
PK pharmacokinetics, PD pharmacodynamics, NA not available
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Thus, the ﬁnal pharmacokinetic–pharmacodynamic model was
used to evaluate different dosing regimens designed to increase
drug exposure in this group of children. The protocol regimen,
the standard WHO 2010 treatment regimen and the updated
increased dose treatment regimen (WHO 2015) were used for
simulations (Supplementary Table 2). Simulated concentration-
time proﬁles of the standard WHO 2010 treatment regimen and
the increased treatment dose regimen resulted in 75% and 50%,
respectively, of simulated day 7 venous plasma concentrations
falling below the previously deﬁned threshold of 30 ng mL−1 for
treatment therapeutic success (Fig. 2)24. The predicted cumulative
malaria incidences in children of 4–20 kg body weight were
estimated to be 33.0% (95% CI: 24.0–43.3%) and 22.5% (95% CI:
17.5–34.5%) at day 60 after a single treatment of the standard
WHO 2010 dosing regimen and the increased dosing regimen,
respectively. The predicted cumulative malaria incidences in
children of 4–20 kg body weight at day 120 were predicted to be
27.0% (95% CI: 14.5–45.0%) and 16.5% (95% CI: 9.00–26.0%)
after three months of SMC using the WHO 2010 dosing regimen
and the increased dosing regimen, respectively (Figs. 3, 4 and
Table 3). However, the predicted cumulative malaria incidences
during three months of active SMC (i.e. 0–90 days) were pre-
dicted to be 12.0% (95% CI: 4.23–27.0%) and 5.0% (95% CI:
1.50–10.5%) according to the WHO 2010 and WHO 2015 dosing
regimens, respectively. Irrespective of the dose regimen, total
malaria incidence doubled between day 90 and 120, suggesting
that another SMC dose at day 90 is needed (i.e. four months of
SMC) in this region. The predicted cumulative malaria incidence
at day 120 was 13.0% (95% CI: 0.40–30.0%) and 5.50% (95% CI:
1.50–11.5%) after four months of SMC with the WHO 2010 and
WHO 2015 dosing regimens, respectively.
Discussion
DHA-PQ is a well-tolerated, safe and effective malaria treat-
ment25. It is also under evaluation as preventive therapy in high-
risk groups, such as young children living in areas of high
transmission4. Antimalarial treatment dosing for the paediatric
population has traditionally been prescribed based on a linear
extrapolation from adult dosing43. This simple extrapolation fails
to take into account the non-linear relationship between body
weight and pharmacokinetic parameters determining exposure
(i.e. elimination clearance). This has resulted in lower exposures
to piperaquine in small children and an increased risk of ther-
apeutic failures, which would be expected to promote the emer-
gence of drug resistant parasites10,23. As chemoprevention,
monthly DHA-PQ exhibited an excellent protective effect against
malaria in children3,4. Several studies have characterized the
pharmacokinetic properties of piperaquine in African children
using both non-compartmental approaches and non-linear
mixed-effects modelling10,27–29. Beyond extrapolation from the
treatment studies, dosing has not been evaluated extensively for
SMC.
In this population pharmacokinetic–pharmacodynamic
assessment there were not enough sparse capillary and venous
plasma concentration measurements (~3–4 samples per indivi-
dual) to develop a pharmacokinetic model with a good degree of
precision. Thus, a frequentist prior approach was applied in order
Table 2 Parameter estimates from the ﬁnal pharmacokinetic–pharmacodynamic model of piperaquine in children receiving
seasonal malaria chemoprevention in Burkina Faso
Parametersa Prior estimatesb Population estimatesc 95% conﬁdence intervald %RSEd
Pharmacokinetics
MTT (h) 2.15 1.37 0.506–1.93 26.9
CL/F (L h−1) 7.50 7.36 7.52–7.84 1.04
VC/F (L) 247 314 282–356 5.80
Q1/F (L h−1) 13.1 9.78 6.89–12.7 15.1
VP1/F (L h−1) 254 274 266–284 1.69
Q2/F (L) 10.8 10.8 10.5–11.1 1.30
VP2/F (L h−1) 3340 3490 3410–3580 1.30
ConversionCAP-VEN — 0.380 0.313–0.450 8.99
σCP — 0.305 0.256–0.346 7.76
σVP — 0.666 0.489–0.797 11.9
Covariates
Relative F — 0.726 0.675–0.781 3.71
Inter-individual variability (%CV)
MTT (h) 0.494 (79.9) 0.574 (88.1) 0.440–0.827 9.35
CL/F (L h−1) 0.0433 (21.0) 0.0438 (21.2) 0.0362–0.0540 5.30
VC/F (L) — 0.665 (97.2) 0.0825–1.14 18.8
Q2/F (L) 0.0487 (22.3) 0.0478 (22.1) 0.0444–0.0531 2.37
VP2/F (L h−1) — 0.0486 (22.3) 0.00000486–0.283 65.0
F 0.0735 (27.6) 0.114 (34.7) 0.0805–0.164 9.40
Pharmacodynamics
BASE (year−1) — 6.28 5.13–11.2 9.35
IC50 (ng mL−1) — 3.66 2.09–5.40 15.1
γ — 1.79 1.12–2.45 12.5
aBASE baseline hazard, CL elimination clearance, ConversionCAP-VEN proportional conversion factor between capillary and venous drug measurements, F relative bioavailability, γ shape factor, IC50
piperaquine venous plasma concentrations associated with a reduction of the baseline hazard by 50%, MTT mean absorption transit time, Q intercompartment clearance, σCP variance of proportional
residual error of the capillary samples, σVP variance of proportional residual error of the venous samples, VC central volume of distribution, VP peripheral volume of distribution
bThe ﬁnal model and parameter estimates from the pharmacokinetic study of piperaquine in children10 were used as prior parameter estimates
cComputed population mean parameter estimates from NONMEM were calculated for a typical child of 18.0 kg body weight. The coefﬁcient of variation (%CV) for inter-individual variability was
calculated as 100 ´
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
exp ω2ð Þ  1
p
dComputed from the non-parametric bootstrap method of the ﬁnal pharmacokinetic model (n= 1000), and pharmacodynamic model (n= 500). The 95% conﬁdence intervals are based on the 2.5th and
97.5th percentile of the bootstrap parameter estimates, and the % relative standard errors (%RSE) are computed as 100 × (standard deviation/mean value)
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08297-9
4 NATURE COMMUNICATIONS |          (2019) 10:480 | https://doi.org/10.1038/s41467-019-08297-9 | www.nature.com/naturecommunications
to stabilize the structural model. The prior model was developed
on dense data collected from a treatment study in children (2–10
years of age) that was conducted in the same region10 and should
therefore be generalizable to the study population presented here.
All pharmacokinetic parameters, inter-individual variability, and
uncertainty measurements were included, and the developed
model was penalised for model estimates, which were far from
prior estimates. The pharmacokinetic parameter estimates were
therefore centralised to the median body weight in the prior
model and scaled with a ﬁxed allometric function. The prior
pharmacokinetic model was a ﬂexible transit-compartment model
followed by a three-compartment disposition model, which is in
agreement with recent pharmacokinetic publications on piper-
aquine in children, adults and pregnant women8,10,22,30.
Almost all venous plasma samples were collected at the same
time-points as capillary plasma samples, and results showed
strong correlation between capillary and venous concentration
measurements (Supplementary Figure 1). However, capillary
piperaquine concentrations were estimated to be substantially
higher than venous measurements (163%) in the same patient,
similar to the linear regression model (Supplementary Figure 1)
and to results from previous reports22,31. Incorporation of an
estimated conversion factor in the population pharmacokinetic
model allowed for simultaneous ﬁt of both capillary and venous
concentrations, which increased the amount of data and so
improved model stability. The conversion factor was somewhat
higher than that previously reported in patients with falciparum
malaria (90%) and vivax malaria (41%)22,31. The exact reason for
higher observed concentrations in capillary plasma compared to
venous plasma could not be elucidated from the data in this
study, but capillary samples are affected by peripheral perfusion
and tissue ﬂuid concentrations as they contain a variable
admixture of interstitial ﬂuid. Differences in this estimated con-
version factor might result from a relatively small number of
venous samples in this study and also a different population
compared to that studied previously (African children vs Asian
adults).
A categorical study covariate was necessary to compensate for
an unexplained lower body weight-normalised exposure in the
present study compared to that in the older children used in the
prior model. The data collected in this study were not sufﬁcient to
explain this discrepancy. A difference in diet could explain dif-
ferences in exposure, since piperaquine absorption is increased
when it is administered together with a high fat meal14.
Maturation effects and other possible admission covariates could
not explain the lower exposure in this study.
The long terminal elimination half-life of piperaquine (median
of 21.3 days, 95% CI: 19.8–25.4 days) resulted in drug accumu-
lation with 23% and 30% higher exposures to piperaquine in
treatment periods two and three, respectively, compared to the
ﬁrst treatment period. This was in agreement with the observed
data showing increasing concentrations over time, with median
day 7 piperaquine capillary plasma concentrations of 35.6, 48.3,
and 57.6 ng mL−1 after the ﬁrst, second, and third month of
SMC, respectively. The ﬁnal pharmacokinetic model showed
good predictive performance and was therefore deemed suitable
to be implemented in the pharmacokinetic–pharmacodynamic
model.
Malaria infections on admission and during follow-up were not
PCR genotyped, and it was, therefore, not possible to distinguish
new from recrudescent infections, and thereby assess treatment
outcomes. However, in previous studies from Africa, DHA-PQ
has shown excellent treatment efﬁcacy, with very few recrudes-
cent infections after therapy. Malaria infections during
the 107 days of follow-up were described successfully with a time-
to-event model, assuming a constant baseline hazard. Such
time-to-event models have been used previously to describe time-
to-malaria re-infections19,22. The implemented model estimated a
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Fig. 1 Visual predictive checks of the ﬁnal population pharmacokinetic and pharmacodynamic model of piperaquine. a The ﬁnal population pharmacokinetic
model, b the interval-censoring time-to-event model of the internal data, and c the ﬁnal pharmacodynamic model predicting the external data. Open circles
represent observed capillary plasma piperaquine concentrations and open triangles represent observed venous plasma concentrations. A solid line
represents the median observed plasma concentrations and dashed lines represent the 5th and 95th percentiles of the observed plasma concentrations.
Shaded areas represent the predicted 95% conﬁdence intervals of each percentile. Solid lines in panel (b) and (c) represent observed Kaplan–Meier
survival plots. Shaded areas represent the 95% prediction intervals
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baseline hazard of 6.28 (95% CI: 5.50–14.2) malaria infections per
year. Similarly, the reported incidence rate in children in Burkina
Faso was 5.0 (95% CI: 4.8–5.2) infections per year32. As the
current study was performed during the high malaria transmis-
sion season, a higher baseline hazard was expected in the current
study. Individually estimated piperaquine concentrations were
implemented with a sigmoidal EMAX-type model to describe the
prevention of new malaria infections during SMC. The estimated
piperaquine venous concentration needed to reduce the baseline
hazard by 50% (IC50) was 3.66 ng mL−1 (equivalent to the
capillary plasma concentrations of 9.62 ng mL−1), which is close
to that previously estimated in adults in Thailand before the
recent emergence of piperaquine resistance22. Observed para-
sitaemia at the time of malaria detection was used to back-
extrapolate a starting time interval of emerging asexual blood
stage infections19. The parasite multiplication rate and length of
parasite life cycle are known to vary between patients, i.e. pre-
viously published results present a 90% prediction interval
between 5.5-fold and 12.3-fold per 48 hours33. Therefore, since
the parasite growth rate was not observed in this study, the
growth rate was assumed to vary between 5-fold and 10-fold per
48 h. This extrapolated interval-censoring approach should pro-
duce more biologically accurate parameter estimates and reﬂect
the residual piperaquine concentrations needed to prevent the
multiplication of parasites emerging from the liver (at a biomass
of 104–105 parasites). However, the observed microscopy detec-
tion limit of circulating parasites coincides with the pyrogenic
density of approximately 108 parasites34. Thus, any sub-
microscopic and asymptomatic infections present at the
monthly round of SMC were assumed to be completely cleared by
the administered drugs, since dihydroartemisinin eliminates ~104
parasites per 48 h (i.e. a standard 3-day treatment is expected to
eliminate all asymptomatic infections)35,36. Therefore, the time-
to-event model included a categorical dihydroartemisinin drug
effect to improve further the mechanistic characterisation of SMC
with artemisinin-based combination therapies. A weekly dosing
regimen has been suggested to be superior to the monthly regi-
men in SMC37. However, the weekly dosing would not necessarily
be reﬂected by the three-day dosing of dihydroartemisinin com-
ponent in this model since it assumes that the full 3-day treat-
ment would completely eliminate circulating parasites. A
prospective study comparing monthly and weekly SMC is needed
in order to establish the optimal dosing strategy in SMC.
The predicted MIC value of piperaquine in these children was
estimated based on the likely starting time of blood stage infections.
Thus, this value should represent the venous plasma concentration
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needed to suppress the parasite multiplication rate to one, and
therefore signify a realistic target concentration for preventive
chemotherapy. The venous plasma MIC was estimated at 12.9 to
17.5 ngmL−1. This predicted MIC range was of similar magnitude
to ex-vivo assessments of IC50 values for the piperaquine sensitive
isolates in this region, i.e. the geometric mean IC50 for piperaquine
was 20.8 ngmL−1 (range: 4.18 to 42.2 ngmL−1) in Cameroon38
and 17.2 ngmL−1 (IQR: 9.16 to 24.8 ngmL−1) in Kenya. The IC50
of piperaquine from P. falciparum community isolates in Uganda
decreased from 10.2 ngmL−1 (95% CI: 9.16–11.5 ngmL−1)39 in
2010–2013 to 4.01 ngmL−1 (95% CI: 3.21–4.98 ngmL−1) in
201640. For successful chemoprevention, piperaquine concentra-
tions should be maintained above the MIC value in order to
eliminate all residual parasites and to prevent new infections
arising during the rainy season.
The ﬁnal pharmacokinetic–pharmacodynamic model illu-
strated clearly the beneﬁt of SMC during the high malaria
transmission season in Burkina Faso. Intermittent preventive
DHA-PQ treatment in adult subjects in Thailand demonstrated
that the subjects with a monthly trough piperaquine plasma
concentration above 31 ng mL−1 did not have any malaria epi-
sodes18. However, using the previously recommended ﬁxed daily
dosage target of 18 mg/kg of piperaquine resulted in 33.0% (95%
CI: 24.0–43.3) of children having a malaria episode during the
60 days of follow-up period (post-SMC). In updated 2015
guidelines, the WHO recommended an increase in the dosage of
DHA-PQ for malaria treatment in young children26. Based on
large-scale SMC simulations using the ﬁnal
pharmacokinetic–pharmacodynamic model, an increased piper-
aquine dosage would have reduced the number of children with
sub-therapeutic day 7 concentrations from 50% to 25% using the
threshold of 30 ng mL−1. The simulated peak piperaquine con-
centrations after an increased dosage were 314 ng mL−1 (95% CI:
97.8–1120 ng mL−1), which was similar to values obtained in
adults treated for malaria41. The simulated increased dosage
would have reduced the predicted cumulative malaria incidence
at day 120 by 38.8% in children at 4–20 kg body weight when
administered as three months of SMC. However, most of the
predicted malaria incidence occurred between day 90 and 120,
suggesting that one additional monthly round of SMC is needed
in this area. The predicted malaria incidence at day 120 after four
months of SMC was similar to the incidence at day 90 after three
rounds of SMC, indicating that one additional month of SMC
could have a substantial impact on the malarial incidence in this
region. Thus, we propose that the increased piperaquine dosage
recommended for the treatment of small children (WHO 2015
guideline) should be applied to SMC as well. If DHA-PQ is used
for SMC, an extended dosing schedule (i.e. four months of SMC)
should be applied to cover the high malaria transmission period.
This is consistent with current policy for SMC with SP plus
amodiaquine in Burkina Faso where SMC is provided for four
months.
In conclusion, the pharmacokinetic and pharmacodynamic
properties of DHA-PQ were characterised during SMC in young
children in Burkina Faso. Modelling and simulation predicted
that, compared to the previously recommended dosage, the
recently recommended increased dosage would reduce the
malaria incidence by 38.8% in small children when administered
as three months of SMC. Extending this therapy from three to
four months of SMC with an increased dosage reduced the
120 days cumulative malaria incidence by 66.7%. If SMC with SP
plus amodiaquine in West and Central Africa starts to lose efﬁ-
cacy because of drug resistance, DHA-PQ could be used as an
alternative regimen. In parts of Southeast Africa, where trans-
mission is highly seasonal but drug resistance to SP prevents the
used of SMC with SP plus amodiaquine, DHA-PQ could also be
used for SMC. Our study shows that if DHA-PQ is used for SMC,
monthly treatment using the new dosing regimen should be
substantially more effective in preventing malaria than the cur-
rently recommended regimen.
Methods
Study design and ethical approval. This study was part of a randomised clinical
trial to compare the protective efﬁcacy of SP and amodiaquine and DHA-PQ for
SMC in children at high risk of malaria, at three rural health facilities in the district
of Lena located 40–50 km from Bobo-Dioulasso, the second largest city of Burkina
Faso. This is an area of intense seasonal transmission with entomological inocu-
lation rates during the dry and the rainy season months of 3.6 and 533 infective
bites per person per year, respectively42. 754 children received DHA-PQ. A subset
of 45 children was identiﬁed at randomisation for assessment of biochemical and
haematological parameters, 15 children to be assessed after each of the SMC
rounds in August, September, and October. A subset of 210 children in the DHA-
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PQ group was identiﬁed at randomisation to give blood samples for evaluation of
the pharmacokinetic properties of piperaquine in the nested PKPD group of the
study; 70 children were randomised to be sampled in August, 70 in September, and
70 in October. The children without blood samples were consider as a PD group
(562 children) for external model validation. Individuals who provided insufﬁcient
information for pharmacokinetic modelling were omitted from this study. No
pharmacokinetic data were collected in the SP and amodiaquine arm. Clinical
details and results are reported in full elsewhere6. Study approval was obtained
from the ethics committees of the London School of Hygiene and Tropical Med-
icine, United Kingdom, and the ethics committee of the Centre Muraz (Comité
d’Ethique Institutionnel du Centre Muraz), Burkina Faso. The study was registered
at www.clinicaltrial.gov (NCT00941785). The inclusion criteria were as follows: age
between 3 and 59 months, expected to stay in the study area during the study
period, no history of allergy to the study medication, and no chronic condition
requiring hospitalization (e.g. severe malnutrition). The presence of malaria at
enrolment was not an exclusion criterion; if malaria was diagnosed, the patient was
enroled and treated with artemether-lumefantrine (Coartem®), and the SMC was
not given, but the child was eligible to received subsequent monthly doses of SMC.
The study was explained to the guardians in their own language, and written
informed consent was obtained from all participants before enrolment. After initial
enrolment, children returned to visit the study clinic monthly for clinical exam-
ination and for SMC drugs to be administered. Field workers visited the children at
home for the next 2 days to supervise drug administration. The home visits were
performed once every two weeks and any child who was unwell was referred to the
clinic for assessment and care by a study physician.
Drug regimens. Children, 2.33–58.1 months of age, received a three-day ﬁxed oral
combination of DHA-PQ (Duocotexin®, Beijing Holley-Cotec Pharmaceutical,
China, 40 mg dihydroartemisinin and 320 mg piperaquine tetra-phosphate per
tablet) once a month for three consecutive months during the malaria seasonal
(August – October, 2009). Dosing was administered according to standard weight-
based treatment dosing guidelines, rounded to the nearest quarter tablet, with a
target dose of 2 mg kg−1 day−1 of dihydroartemisinin and 18 mg kg−1 day−1 of
piperaquine phosphate43. All drug administrations were supervised, and the date
and time of administration was recorded. DHA-PQ was administered as whole
tablets or fractions of tablets on an empty stomach with a glass of water. Tablets
were crushed, mixed with water, and administrated as a slurry to the children who
could not ingest the tablets. Children were observed for 30 min after dosing to
ensure that the medication was not vomited. Children who did vomit within 30
min of drug administration received an additional dose, and were subsequently
excluded from the pharmacokinetic–pharmacodynamic analysis from that time
point. All microscopy conﬁrmed malaria cases were treated with a full treatment
dose of artesunate-lumefantrine (Coartem®) and these children then excluded from
further analysis from the time of treatment.
Blood samples. All children in the nested pharmacokinetic–pharmacodynamic
study contributed a baseline ﬁnger prick capillary blood sample (~200 μl) before
antimalarial treatment. One hundered and seventy-nine children were randomly
allocated to be sampled during the three months of SMC (32 children were sam-
pled in August, 92 children in September, and 55 children in October). Four ﬁnger
prick samples were taken randomly from each child in pre-speciﬁed sampling
windows (pre-dose, 0–6 days, day 7, and 8–30 days after the ﬁrst day of dosing).
One venous sample (~2 ml) was taken from 40 children at the same time as the
second, third, or fourth ﬁnger prick sample. Finger prick samples and plasma
samples were stored at −80 °C until shipment on dry ice to the Department of
Clinical Pharmacology, Mahidol-Oxford Tropical Medicine Research Unit
(MORU), Bangkok, Thailand. Malaria was diagnosed using thick and thin blood
smears, stained with 2% Giemsa for 30 min and examined in double readings by
experienced laboratory technicians.
Piperaquine quantiﬁcation. Piperaquine concentrations were measured using
solid phase extraction followed by liquid chromatography coupled with tandem
mass spectroscopy according to a previously published method44. Quality control
samples at 4.5, 20, and 400 ng mL−1 were analysed in triplicate within each batch
of clinical samples to ensure the accuracy and precision of the assay. The relative
standard deviation (%RSD) at low, middle, and high concentrations were 3.90%,
2.04%, 2.42% for venous samples and 5.29%, 4.51%, 3.69% for capillary samples.
The limit of detection (LOD) and the LLOQ of both venous and capillary plasma
samples were set to 0.375 and 1.50 ng mL−1, respectively. The laboratory is a
participant in the QA/QC proﬁciency testing programme supported by the
Worldwide Antimalarial Resistance Network (WWARN)45.
Pharmacokinetic analysis. Piperaquine capillary and venous plasma concentrations
were transformed into their natural logarithms. Modelling and simulation was per-
formed using NONMEM version 7.3 (Icon Development Solution, Ellicott City, MD).
Piranha 2.946, and Perl-speaks-NONMEM (PsN; version 4.4.0)47 were used for
automation and diagnostics during the model building process. The concentration-
time proﬁle was characterised using non-linear mixed-effects modelling with the ﬁrst-
order conditional estimation method with interactions in NONMEM. The limited
observed concentrations (~3–4 samples per individual) were not deemed sufﬁciently
informative to characterise adequately the known multi-phasic pharmacokinetic
proﬁle of piperaquine. Typical pharmacokinetic parameter estimates and inter-
individual variability estimates from a treatment study in children from the same
region were therefore incorporated by using the $PRIOR functionality in NON-
MEM48. The prior pharmacokinetic model was a ﬂexible two-transit absorption
compartment model followed by a three-compartment disposition model, including
body weight as a ﬁxed allometric function on all clearance and volume parameters10.
A linear association between capillary and venous plasma concentrations was hypo-
thesized and then modelled using an estimated conversion factor at the population
level. Inter-individual variability of the pharmacokinetic parameters was assumed to
be log-normally distributed with a zero mean and ω2 variance (Eq. 1). The unex-
plained residual variability was modelled separately for capillary and venous plasma
concentrations and implemented as proportional error models on the log-
transformed concentrations, essentially equivalent to proportional errors on an
arithmetic scale. Body weight (BW) was introduced as an allometric function for all
clearance (exponent of n= 0.75) and volume (exponent of n= 1.00) parameters,
centralized to 18 kg of body weight according to the typical patient in the prior model
(Eq. 1). A maturation process of enzyme-dependent metabolic elimination was
evaluated based on the elimination clearance of piperaquine (Eq. 2)49.
θi ¼ θ ´ exp ηi;θ
 
´
BWi
18:0
 n
ð1Þ
MF ¼ PMA
HILL
TMHILL50 þPMAHILL
ð2Þ
where θi is the individual pharmacokinetic parameter estimate of the i
th subject, θ is
the typical population parameter estimate, ηi;θ is the inter-individual variability, MF is
the maturation factor, PMA is the post-menstrual age, HILL is the Hill coefﬁcient,
and TM50 is the maturation half-time. Inter-study differences between the current
study and the prior study were investigated by applying a categorical study covariate
on all pharmacokinetic parameters. All other covariates (parasitaemia, gender, age,
Table 3 Simulated malaria incidence in children given DHA-PQ seasonal malaria chemoprevention, following the WHO 2010 and
2015 dosing recommendations
Dosing regimen (WHO 2010) Increased dosing regimen (WHO 2015) Relative reduction (%)
Malaria incidence (%) at day 60, a single
treatment
33.0 (24.0–43.3) 22.5 (17.5–34.5) 32.3
Malaria incidence (%) at day 120, three months
of SMC
27.0 (14.5–45.0) 16.5 (9.00–26.0) 38.8
Malaria incidence (%) at day 90, three months
of SMC
12.0 (4.23–27.0) 5.00 (1.50–10.5) 58.3
Malaria incidence (%) at day 120, four months
of SMC
13.0 (0.40–30.0) 5.50 (1.50–11.5) 57.6
All values are reported as median (95% conﬁdence interval) unless otherwise speciﬁed
SMC seasonal malaria chemoprevention, WHO World Health Organization
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and nutritional status) were investigated by a stepwise addition (p < 0.05) and elim-
ination (p < 0.01) approach, using linear, exponential, and power functions.
Pharmacodynamic analysis. The ﬁnal pharmacokinetic model and its typical
parameter estimates were ﬁxed, and the time interval to malaria infection during
the follow-up period was modelled using a time-to-event analysis. Time to the ﬁrst
malaria episode or being lost/censored during ﬁve months of follow-up were used
as primary outcome data for the pharmacodynamic model. Non-linear mixed-
effects modelling with the Laplace estimation method with interactions was applied
throughout the pharmacokinetic–pharmacodynamic modelling approach.
The protective effect of piperaquine (PQEFF, Eq. 3) was deﬁned by a sigmoidal
EMAX function, where EMAX is the maximal drug effect, CP(t) is the
predicted venous piperaquine plasma concentration at time t, IC50 is the venous
piperaquine plasma concentration needed to reduce the hazard of malaria infection
by 50%, and γ is a shape parameter. The effect of dihydroartemisinin (DHAEFF)
was implemented as a categorical function reducing the hazard of malaria infection
to zero, six days before a treatment dose (see below) and during the three days of
treatment in each period (Eq. 4). A blood stage infection was assumed to start at
~105 parasites emerging from the liver, and the microscopy detection limit of
malaria was set to be approximately equal to a total parasite biomass of 108
parasites. Thus, assuming an approximate 10-fold multiplication rate every 48 h in
the absence of drug, a blood stage infection starting between 0 and 6 days before
treatment would not be detected, since the exposure to dihydroartemisinin would
eliminate such an infection before reaching a microscopy detectable parasite
density.
PQEFF ¼ 1
EMAX ´CP
γ tð Þ
ICγ50 þ CPγ tð Þ
ð3Þ
DHAEFF ¼
0 ; from 6 days before the first dose to 24 hours after the last dose
1 ; otherwise

ð4Þ
A constant baseline hazard of malaria infection during the high-transmission
season was assumed, and the hazard function (Hz(t)) was deﬁned by multiplication
of the constant baseline hazard θBASEð Þ, piperaquine drug effect (PQEFF), and
dihydroartemisinin drug effect (DHAEFF), as illustrated in equation 5. The survival
function was calculated as the exponent of the cumulative hazard (Eq. 6) and the
probability density function for acquiring a malaria infection at a speciﬁc time
point (P(t)) was therefore deﬁned as the product of the hazard function with the
survival function (Eq. 7).
Hz tð Þ ¼ θBASE ´ PQEFF ´DHAEFF ð5Þ
S tð Þ ¼ exp 
Zt
0
Hz tð Þdt
0
@
1
A ð6Þ
P tð Þ ¼ S tð Þ ´Hz tð Þ ð7Þ
Different levels of parasitaemia at the time of malaria detection during the follow-
up period indicated that the time of emerging blood stage infections might differ
among subjects. The lag-time between emerging blood stage infections from the
liver and the microscopy detection of parasites is dependent on several factors, i.e.
parasite growth rate, number of parasites emerging from the liver, and drug
concentration, as well as the quality of microscopy. The growth rate of malaria
parasites is variable, particularly in a context of variable immunity, and is even
more uncertain during the terminal elimination phase of a slowly eliminated
antimalarial drug33. Therefore, the time interval before emergence of blood stage
infection from the liver was back-extrapolated based on the observed number of
detected parasites (PAROBS)19,33,50. To account for the uncertainties noted above,
the start time of the interval (IStart; Eq. 8) was approximated by assuming a
relatively small number of blood stage parasites emerging from the liver (~104
parasites) and a lower than maximum growth rate (KGrowth, slow; 5-fold increase
every 48 h). The end time of the interval (IEnd; Eq. 9) was approximated by
assuming a relatively large number of blood stage parasites emerging from the liver
(approximately 105 parasites) and an unrestrained growth rate (KGrowth, fast; 10-fold
increase every 48 h). This scheme is illustrated in Supplementary Figure 3. The ﬁnal
pharmacodynamic model was based on an interval-censoring time-to-event
approach, accounting for the likely interval of emerging blood stage infections
according to equations 10–11. Thus, the probability of an event occurring within
this interval IStart<t<IEndð Þ was determined by equation 10, as compared to the
probability of an event occurring in patients with no detected parasitaemia during
follow-up time period (T) according to equation 11.
IStart ¼
1
KGrowth; slow
´ ln
PAROBS
104
 
ð8Þ
IEnd ¼
1
KGrowth; fast
´ ln
PAROBS
105
 
ð9Þ
P IStart<t<IEnd θjð Þ¼ 1 S IEndð Þ  S IStartð Þ½  ð10Þ
P t>T θjð Þ ¼ S Tð Þ ð11Þ
Biologically plausible covariates (body weight, gender, and age) were evaluated with
a stepwise approach as linear and exponential functions on baseline hazard in the
ﬁnal time-to-event model. Also, individually predicted venous plasma piperaquine
drug concentrations at the back-extrapolated start of blood stage infections were
estimated and summarised as conservative estimates of the MIC values for clinical
infections, assuming very high-transmission intensity. Similarly, individually
predicted piperaquine trough concentrations were assumed to be the maximum
MIC values for patients who did not present with recurrent infections (i.e. realistic
MIC values for patients without reinfections are likely to be lower). Thus, to avoid
any potential bias towards lower target drug concentrations, the 95th percentile of
individually predicted MIC values was calculated and presented as a clinical target
MIC.
Model diagnostics. The pharmacokinetic and pharmacodynamic models were
diagnosed by using both internal and external validation.
The objective function value (OFV), calculated by NONMEM as proportional
to –2 × log-likelihood of data, was used to evaluate competing nested models. A
reduction in OFV (ΔOFV) is equivalent to a likelihood ratio test (LRT) and the
ΔOFV of 3.84, 6.63, and 10.8 was considered signiﬁcant with a p-value of 0.05, 0.01,
and 0.001, respectively, for two nested models with one degree of freedom
difference. Shrinkage values were used to evaluate the reliability of the goodness-of-
ﬁt diagnostics, where high shrinkage values reﬂect a lower accuracy of individual
predictions. A prediction-corrected visual predictive check (n= 2000 simulations)
was applied to the ﬁnal pharmacokinetic model in order to determine the
predictive power of the model on the low (5th), median (50th), and high (95th)
percentiles51. A visual predictive check of the time-to-event model was obtained by
visualising the observed Kaplan–Meier plot with the 95% conﬁdence interval of
simulated events (n= 1000). As external validation, the ﬁnal time-to-event model
and the demographic and dosing information from the larger PD group (n= 562)
were used to simulate 1000 new clinical studies. The simulated times to malaria
infection were overlaid with the observed incidence of malaria in the same group.
Non-parametric relative standard errors (%RSE) and model robustness were
assessed by bootstrapping diagnostics (n= 500). All diagnostic procedures were
implemented by using PsN.
Pharmacokinetic–pharmacodynamic outcome simulations. The ﬁnal
pharmacokinetic–pharmacodynamic model was used to simulate the antimalarial
protective effect of DHA-PQ after different dosing regimens (Supplementary
Table 2). Pharmacokinetic concentration-time proﬁles of 1000 children at each kg
body weight (4–20 kg) were simulated and day 7 concentrations and peak piper-
aquine concentrations were summarised and compared between dosing strategies.
The ﬁnal time-to-event model was used to simulate the therapeutic outcome,
stratiﬁed by body weight (n= 200 individuals per body weight, 100 replicates), in
order to compare the malaria incidence between children receiving the standard
WHO 2010 regimen52,43 and children receiving the WHO 2015 suggested
increased dosing regimen, based on Tarning et al.10,26. The therapeutic outcomes of
a single treatment, three months of SMC, and four months of SMC were simulated
and compared in order to determine the optimal dosing scenario.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data and NONMEM code for the pharmacokinetic and pharmaco-
dynamic model are available from the authors upon reasonable request.
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